PATH-MVI and US FDA to collaborate on malaria vaccine testing
This article was originally published in Scrip
The PATH Malaria Vaccine Initiative is providing the US FDAwith about $1.5 million over three years to develop laboratory tests for evaluating malaria vaccines early in the development process. The collaboration, which is being carried out under a co-operative research and development agreement, will help develop tests to assess whether a vaccine candidate based on live, attenuated malaria parasites is safe enough to begin Phase I clinical testing. The project also will support development of other attenuated sporozoite vaccines, specifically those that are genetically attenuated, PATH-MVI said.
You may also be interested in...
Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic
New approaches include delivering study drug from a clinical site directly to a patient’s house through a courier service, as well as use of drones and automated dispensing units; future trials could see a mix of delivery approaches.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.